BioSpace

‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise

Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range for a takeout.

By BioSpace

1 min read
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights